骨保护素基因突变导致焦磷酸钙沉积病的 CCAL1 位点。

Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease.

机构信息

Cooper Medical School of Rowan University, Camden, NJ, United States.

John T Mather Memorial Hospital-SUNY Stony Brook, Port Jefferson, NY, United States.

出版信息

Osteoarthritis Cartilage. 2018 Jun;26(6):797-806. doi: 10.1016/j.joca.2018.03.005. Epub 2018 Mar 22.

Abstract

OBJECTIVE

Mutations on chromosomes 5p (CCAL2) and 8q (CCAL1) have been linked to familial forms of calcium pyrophosphate deposition disease (CPDD). Mutations in the ANKH gene account for CCAL2, but the identity of CCAL1 has been elusive. Recently, a single Dutch kindred with a mutation in the Tumor Necrosis Factor Receptor Super Family member 11B (TNFRSF11B) gene coding for osteoprotegerin (OPG) was described as a gain-of-function mutation. Affected family members had premature generalized osteoarthritis (PGOA) and CPDD. As the TNFRSF11B gene is on 8q, we sought additional evidence that TNFRSF11B was CCAL1, and investigated potential disease mechanisms.

DESIGN

DNA from two novel PGOA/CPDD families was screened for sequence variants in the TNFRSF11B gene. Mutations were verified by genotype analysis of affected and unaffected family members. We also investigated effects of normal and mutant OPG on regulators of CPP crystal formation in porcine cartilage.

RESULTS

The identical TNFRSF11B mutation described in the Dutch family was present in two novel PGOA/CPDD families. ANKH was normal in affected patient fibroblasts. Exogenous OPG did not alter ANKH mRNA or protein levels, affect translocation of ANKH to the membrane, nor increase [pyrophosphate (PPi)] or other key regulators of CPDD.

CONCLUSION

We have firmly established the identity of CCAL1 as TNFRSF11B (OPG). Our findings suggest that this mutation produces disease in an ANKH-independent manner via novel mechanisms not primarily targeting cartilage. This work rationalizes further investigation of OPG pathway components as potential druggable targets for CPDD.

摘要

目的

染色体 5p(CCAL2)和 8q(CCAL1)上的突变与家族性焦磷酸钙沉积病(CPDD)有关。ANKH 基因突变可导致 CCAL2,但 CCAL1 的身份一直难以确定。最近,一个荷兰家族的单个成员携带肿瘤坏死因子受体超家族成员 11B(TNFRSF11B)基因突变,该基因突变编码骨保护素(OPG),被描述为获得性功能突变。受影响的家族成员患有早发性全身骨关节炎(PGOA)和 CPDD。由于 TNFRSF11B 基因位于 8q 上,我们寻求了 TNFRSF11B 是 CCAL1 的其他证据,并研究了潜在的疾病机制。

设计

对两个新的 PGOA/CPDD 家族的 DNA 进行 TNFRSF11B 基因突变的筛选。通过对受影响和未受影响的家族成员进行基因型分析来验证突变。我们还研究了正常和突变 OPG 对猪软骨中 CPP 晶体形成调节剂的影响。

结果

在荷兰家族中描述的相同 TNFRSF11B 突变存在于两个新的 PGOA/CPDD 家族中。受影响患者成纤维细胞中的 ANKH 正常。外源性 OPG 不会改变 ANKH mRNA 或蛋白水平,影响 ANKH 向膜的易位,也不会增加[焦磷酸盐(PPi)]或 CPDD 的其他关键调节剂。

结论

我们已经确定 CCAL1 的身份为 TNFRSF11B(OPG)。我们的研究结果表明,这种突变以不依赖于 ANKH 的方式通过新的机制导致疾病,而不是主要针对软骨。这项工作合理化了进一步研究 OPG 途径成分作为 CPDD 潜在可药物靶点的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索